Hospital
Maryview Hospital LLC
Maryview Hospital LLC was paid $75.03M by Medicaid between Jan 2018 and Dec 2024, across 452 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoMARYVIEW HOSPITAL LLC
PORTSMOUTH, VA 23707
PORTSMOUTH, VA 23707
33aNPI1750399192assigned 08/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$75.03M
24GClaims2,201,382
24DCodes billed452
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#7 of 80
Median peer was paid$14.69M
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 212,711 | $4.64M | |
| 2019 | 302,224 | $7.99M | |
| 2020 | 268,289 | $10.02M | |
| 2021 | 355,715 | $12.43M | |
| 2022 | 356,625 | $13.32M | |
| 2023 | 387,057 | $14.12M | |
| 2024incomplete | 318,761 | $12.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 74,183 | 62,526 | $10.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 45,397 | 37,929 | $7.15M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.6% | 140,286 | 35,493 | $5.67M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 30,743 | 25,217 | $5.10M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 6.7% | 94,051 | 27,547 | $5.02M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.1% | 15,198 | 11,912 | $3.79M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.6% | 26,962 | 22,642 | $3.47M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 10,223 | 8,857 | $2.10M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.5% | 7,166 | 4,956 | $1.91M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 11,410 | 9,777 | $1.86M |
| 97162 | 1.8% | 12,541 | 11,523 | $1.38M | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 13,539 | 9,476 | $1.36M |
440 more codes
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.4% | 94,472 | $1.07M |
| J2357 | Injection, omalizumab, 5 mg | 1.3% | 2,475 | $970K |
| 97161 | 1.2% | 7,658 | $877K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 6,761 | $854K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 17,786 | $841K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,531 | $741K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,071 | $688K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,257 | $661K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 20,067 | $627K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,129 | $543K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,971 | $542K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,884 | $517K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 11,325 | $515K |
| G0378 | Hospital observation service, per hour | <1% | 4,510 | $507K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,184 | $491K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 958 | $480K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,817 | $460K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,326 | $439K |
| 76642 | <1% | 4,417 | $417K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,826 | $374K |
| 93975 | <1% | 4,196 | $360K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,228 | $359K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,142 | $325K |
| J0517 | Injection, benralizumab, 1 mg | <1% | 238 | $319K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,975 | $313K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,472 | $305K |
| 80053 | Comprehensive metabolic panel | <1% | 77,557 | $291K |
| 97014 | <1% | 9,597 | $283K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,205 | $264K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 496 | $239K |
| 93971 | <1% | 2,763 | $239K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 341 | $220K |
| 97113 | <1% | 4,648 | $214K | |
| 72141 | <1% | 1,324 | $210K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,633 | $201K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 275 | $190K |
| 73221 | <1% | 991 | $188K | |
| 97116 | <1% | 11,936 | $187K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,898 | $172K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,385 | $152K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 308 | $148K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 47,503 | $146K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,320 | $143K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,241 | $140K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 533 | $139K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,441 | $137K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 56 | $137K |
| 96415 | <1% | 700 | $136K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14,484 | $130K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,390 | $128K |
| 71250 | <1% | 2,182 | $128K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,585 | $121K |
| 76536 | <1% | 1,118 | $116K | |
| 93970 | <1% | 1,070 | $116K | |
| 76770 | <1% | 1,028 | $113K | |
| 80061 | Lipid panel | <1% | 16,313 | $110K |
| 97165 | <1% | 1,986 | $108K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,066 | $104K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,132 | $102K |
| 12001 | <1% | 530 | $100K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 100,261 | $100K |
| 64483 | <1% | 178 | $99K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,155 | $99K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 20,879 | $95K |
| 96367 | <1% | 2,174 | $94K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,683 | $94K |
| 77066 | Tomosynthesis, mammo | <1% | 2,565 | $87K |
| 71271 | <1% | 832 | $83K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,498 | $82K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,328 | $81K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,875 | $80K |
| 97163 | <1% | 545 | $76K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 46,840 | $73K |
| 77412 | <1% | 143 | $73K | |
| 97166 | <1% | 805 | $73K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,971 | $72K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,811 | $70K |
| 10060 | <1% | 515 | $70K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 792 | $69K |
| 83880 | <1% | 8,865 | $67K | |
| 36430 | <1% | 761 | $65K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 43 | $65K |
| 93458 | <1% | 62 | $65K | |
| 59025 | Fetal non-stress test | <1% | 717 | $64K |
| 70498 | <1% | 394 | $64K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,364 | $63K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14,340 | $63K |
| 97016 | <1% | 2,349 | $62K | |
| 71045 | Radiologic examination, chest; single view | <1% | 22,886 | $58K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 111 | $56K |
| 97035 | <1% | 1,966 | $55K | |
| 70486 | <1% | 1,362 | $54K | |
| J2182 | Injection, mepolizumab, 1 mg | <1% | 94 | $54K |
| 70491 | <1% | 324 | $53K | |
| 93017 | <1% | 586 | $53K | |
| 97018 | <1% | 2,501 | $52K | |
| 19083 | <1% | 51 | $51K | |
| 72100 | <1% | 2,686 | $49K | |
| 96523 | <1% | 620 | $47K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,807 | $45K |
| 77080 | <1% | 825 | $43K | |
| 90715 | <1% | 2,525 | $42K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 277 | $42K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,333 | $41K |
| 86803 | <1% | 3,697 | $41K | |
| 87040 | <1% | 7,536 | $41K | |
| 80050 | General health panel | <1% | 4,333 | $38K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 36,403 | $38K |
| 73030 | <1% | 3,937 | $35K | |
| 72110 | <1% | 1,236 | $35K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,947 | $35K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,006 | $35K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,454 | $32K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 216 | $32K |
| 74246 | <1% | 299 | $31K | |
| 73562 | <1% | 3,078 | $30K | |
| 84439 | <1% | 5,053 | $30K | |
| 95811 | <1% | 55 | $29K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,581 | $28K |
| 12011 | <1% | 157 | $28K | |
| 84484 | <1% | 35,585 | $26K | |
| 77336 | <1% | 324 | $26K | |
| 82607 | <1% | 3,550 | $26K | |
| 77002 | <1% | 192 | $26K | |
| 82728 | <1% | 4,430 | $26K | |
| 95800 | <1% | 162 | $25K | |
| 91200 | <1% | 333 | $25K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 318 | $25K |
| 73630 | <1% | 3,782 | $25K | |
| 82553 | <1% | 10,877 | $25K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 436 | $25K |
| 73700 | <1% | 283 | $25K | |
| J3490 | Unclassified drugs | <1% | 14,453 | $24K |
| 62323 | <1% | 62 | $24K | |
| 49083 | <1% | 37 | $22K | |
| 85027 | <1% | 7,627 | $22K | |
| 43235 | <1% | 66 | $22K | |
| 73502 | <1% | 2,186 | $22K | |
| 73610 | <1% | 3,274 | $21K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 143 | $21K |
| 72040 | <1% | 1,054 | $21K | |
| 97802 | <1% | 517 | $20K | |
| 70496 | <1% | 361 | $20K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 29 | $20K |
| 85379 | <1% | 4,858 | $19K | |
| 73130 | <1% | 3,059 | $19K | |
| 97032 | <1% | 443 | $19K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 135 | $19K |
| 76942 | <1% | 336 | $18K | |
| 73564 | <1% | 1,623 | $18K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,538 | $17K |
| 77062 | <1% | 1,086 | $17K | |
| 74018 | <1% | 1,793 | $17K | |
| 97803 | <1% | 410 | $17K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,342 | $16K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 132 | $15K |
| 83550 | <1% | 4,174 | $15K | |
| 76937 | <1% | 408 | $15K | |
| 76801 | <1% | 183 | $14K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 7,882 | $14K |
| 83540 | <1% | 4,831 | $13K | |
| 90677 | <1% | 166 | $13K | |
| 12002 | <1% | 65 | $13K | |
| 82746 | <1% | 2,531 | $13K | |
| 80076 | <1% | 4,489 | $13K | |
| 95819 | <1% | 66 | $13K | |
| 73560 | <1% | 1,192 | $12K | |
| 77061 | <1% | 826 | $12K | |
| 74183 | <1% | 33 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,755 | $12K |
| 82570 | <1% | 4,070 | $12K | |
| 81001 | <1% | 37,654 | $12K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,820 | $11K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 89 | $11K |
| 81025 | <1% | 26,527 | $11K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 139 | $11K |
| 64450 | <1% | 104 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,629 | $10K |
| 94729 | <1% | 368 | $10K | |
| C1776 | Joint device (implantable) | <1% | 135 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,635 | $10K |
| 73110 | <1% | 1,439 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 27,626 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,565 | $10K |
| 85652 | <1% | 2,280 | $10K | |
| 83970 | <1% | 563 | $10K | |
| G0008 | Administration of influenza virus vaccine | <1% | 528 | $9K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 496 | $9K |
| 29125 | <1% | 84 | $9K | |
| 84153 | <1% | 982 | $9K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 91 | $9K |
| 82565 | <1% | 4,786 | $9K | |
| 82043 | <1% | 3,688 | $9K | |
| 83605 | <1% | 7,528 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 62 | $8K |
| 97012 | <1% | 302 | $8K | |
| 77334 | <1% | 43 | $8K | |
| 99218 | <1% | 980 | $8K | |
| 86850 | <1% | 4,565 | $8K | |
| 81003 | <1% | 17,792 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,252 | $8K |
| 83735 | <1% | 21,087 | $8K | |
| 86140 | <1% | 2,128 | $7K | |
| 76870 | <1% | 88 | $7K | |
| 85610 | <1% | 10,326 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 25,582 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,780 | $7K |
| 90674 | <1% | 260 | $7K | |
| 82962 | <1% | 24,098 | $7K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 309 | $6K |
| 92610 | <1% | 144 | $6K | |
| 73140 | <1% | 1,129 | $6K | |
| 93798 | <1% | 87 | $6K | |
| 94060 | <1% | 111 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 8,285 | $6K |
| 93976 | <1% | 56 | $6K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 32 | $6K |
| 72158 | <1% | 13 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,867 | $5K |
| 86900 | <1% | 5,440 | $5K | |
| 94726 | <1% | 155 | $5K | |
| 77280 | <1% | 19 | $5K | |
| 72070 | <1% | 366 | $5K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 187 | $5K |
| 77295 | <1% | 16 | $5K | |
| 72050 | <1% | 148 | $4K | |
| 85730 | <1% | 5,700 | $4K | |
| 36591 | <1% | 488 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14,896 | $4K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 123 | $4K |
| 84425 | <1% | 405 | $4K | |
| 93308 | <1% | 17 | $4K | |
| 84436 | <1% | 496 | $4K | |
| 80047 | <1% | 1,194 | $4K | |
| 84702 | <1% | 4,452 | $4K | |
| 82550 | <1% | 12,667 | $4K | |
| 90714 | <1% | 183 | $4K | |
| 74178 | <1% | 16 | $4K | |
| 80143 | <1% | 1,345 | $3K | |
| 72131 | <1% | 78 | $3K | |
| 96417 | <1% | 503 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,839 | $3K |
| 80179 | <1% | 1,303 | $3K | |
| 86592 | <1% | 599 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 311 | $3K |
| 73590 | <1% | 834 | $3K | |
| 86923 | <1% | 317 | $3K | |
| 86901 | <1% | 5,437 | $3K | |
| 94762 | <1% | 1,348 | $3K | |
| 80164 | <1% | 422 | $3K | |
| 64415 | <1% | 19 | $3K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 48 | $3K |
| 87077 | <1% | 4,249 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,170 | $3K |
| 83690 | <1% | 20,096 | $3K | |
| 95816 | <1% | 12 | $3K | |
| 85014 | <1% | 1,824 | $3K | |
| 29515 | <1% | 13 | $3K | |
| 84703 | <1% | 9,474 | $2K | |
| 86780 | <1% | 310 | $2K | |
| 95806 | <1% | 14 | $2K | |
| 93922 | <1% | 36 | $2K | |
| 82077 | <1% | 7,849 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,558 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 302 | $2K |
| 43450 | <1% | 48 | $2K | |
| 92526 | <1% | 69 | $2K | |
| 87070 | <1% | 5,123 | $2K | |
| 99152 | <1% | 2,366 | $2K | |
| 74022 | <1% | 496 | $2K | |
| 87340 | <1% | 596 | $2K | |
| 84550 | <1% | 1,091 | $2K | |
| 20610 | <1% | 14 | $2K | |
| 73080 | <1% | 403 | $2K | |
| 73620 | <1% | 299 | $2K | |
| 87186 | <1% | 3,880 | $2K | |
| 80069 | <1% | 354 | $2K | |
| 77300 | <1% | 35 | $2K | |
| 86706 | <1% | 338 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,379 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,156 | $2K |
| 74240 | <1% | 16 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,337 | $2K |
| 74019 | <1% | 137 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 11,476 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,456 | $1K |
| 88304 | <1% | 816 | $1K | |
| 87210 | <1% | 9,346 | $1K | |
| 96376 | <1% | 8,528 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 14 | $1K |
| C1769 | Guide wire | <1% | 2,351 | $1K |
| 73090 | <1% | 290 | $1K | |
| 88307 | <1% | 127 | $1K | |
| 90750 | <1% | 13 | $1K | |
| 97164 | <1% | 39 | $1K | |
| 84100 | <1% | 2,265 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,497 | $990.33 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,359 | $901.53 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,828 | $882.58 |
| 80177 | <1% | 240 | $840.21 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,008 | $820.19 |
| 73120 | <1% | 61 | $776.29 | |
| 87081 | <1% | 2,300 | $769.73 | |
| 83615 | <1% | 177 | $761.03 | |
| 90686 | <1% | 204 | $750.27 | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,887 | $749.82 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,301 | $690.88 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,799 | $680.77 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,948 | $633.11 |
| 85045 | <1% | 518 | $632.56 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,464 | $618.56 |
| 82040 | <1% | 223 | $612.09 | |
| 87205 | <1% | 887 | $607.88 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,530 | $550.80 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,998 | $547.97 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,258 | $450.41 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,653 | $445.19 |
| 82803 | <1% | 1,091 | $442.82 | |
| 84145 | <1% | 538 | $441.39 | |
| 87088 | <1% | 271 | $361.85 | |
| 84132 | <1% | 1,481 | $361.81 | |
| 86480 | <1% | 14 | $350.27 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,216 | $341.73 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,414 | $323.96 |
| J1815 | Injection, insulin, per 5 units | <1% | 1,020 | $317.12 |
| 86431 | <1% | 29 | $315.71 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,091 | $314.91 |
| 87147 | <1% | 1,739 | $309.55 | |
| 74230 | <1% | 20 | $296.48 | |
| 84520 | <1% | 1,085 | $289.55 | |
| 80074 | <1% | 26 | $278.41 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 33 | $251.25 |
| 73600 | <1% | 86 | $237.15 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,860 | $225.97 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $191.30 |
| 88342 | <1% | 144 | $180.21 | |
| 36600 | <1% | 81 | $176.33 | |
| 73552 | <1% | 60 | $162.07 | |
| 82330 | <1% | 282 | $159.13 | |
| 82947 | <1% | 1,284 | $156.54 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 339 | $150.13 |
| 84480 | <1% | 25 | $146.49 | |
| 86235 | <1% | 15 | $145.81 | |
| 86920 | <1% | 94 | $144.44 | |
| 85018 | <1% | 301 | $142.92 | |
| 82435 | <1% | 969 | $132.40 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,991 | $131.96 |
| 51798 | <1% | 42 | $131.96 | |
| 92611 | <1% | 20 | $129.67 | |
| 82274 | <1% | 13 | $119.24 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 597 | $114.63 |
| 71101 | <1% | 40 | $113.25 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 755 | $111.74 |
| 90694 | <1% | 17 | $106.78 | |
| 86038 | <1% | 29 | $103.76 | |
| 82784 | <1% | 14 | $98.08 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 269 | $92.69 |
| 84165 | <1% | 27 | $92.62 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 15 | $84.55 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 405 | $82.77 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,641 | $82.55 |
| 94761 | <1% | 4,688 | $82.43 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,179 | $82.26 |
| 86787 | <1% | 12 | $75.45 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,552 | $67.81 |
| 73660 | <1% | 55 | $64.51 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,985 | $62.78 |
| 82140 | <1% | 94 | $61.46 | |
| 84295 | <1% | 1,065 | $60.84 | |
| 86225 | <1% | 13 | $59.60 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,963 | $58.73 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,533 | $54.94 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 119 | $47.51 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 857 | $41.24 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 714 | $36.69 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 618 | $33.56 |
| 73100 | <1% | 31 | $31.76 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 234 | $22.71 |
| 82150 | <1% | 18 | $21.64 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 458 | $19.19 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 349 | $18.74 |
| 84156 | <1% | 12 | $15.45 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,830 | $14.23 |
| 90653 | <1% | 37 | $13.70 | |
| 96368 | <1% | 214 | $7.22 | |
| 82272 | <1% | 87 | $5.92 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 223 | $3.72 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 201 | $3.22 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 195 | $2.45 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 20 | $2.28 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 56 | $1.49 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 21 | $1.14 |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 485 | $0.34 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 595 | $0.30 |
| A9270 | Non-covered item or service | <1% | 3,904 | $0.14 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 493 | $0.06 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 409 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 91 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 103 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 837 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 198 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 268 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 213 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 102 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 144 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 30 | $0.00 |
| 96377 | 0% | 17 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 120 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 95 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 18 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 17 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 37 | $0.00 |
| 94760 | 0% | 13 | $0.00 | |
| 96411 | 0% | 27 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 12 | $0.00 |
| 73060 | 0% | 13 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 622 | $0.00 |
| C1729 | Catheter, drainage | 0% | 349 | $0.00 |
| 76981 | 0% | 17 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 50 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 115 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 80 | $0.00 |
| 93325 | 0% | 18 | $0.00 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 18 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 68 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 748 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 355 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 1,680 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 16 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 299 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 280 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 242 | $0.00 |
| 73070 | 0% | 12 | $0.00 | |
| A4565 | Slings | 0% | 38 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 19 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 59 | $0.00 |
| 93321 | 0% | 18 | $0.00 | |
| 82800 | 0% | 67 | $0.00 | |
| 99001 | 0% | 16 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.